secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2022-12-09T23:59:59+00:00
Accession:  0001193125-22-301402
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasca licenses naporafenib from Novartis for $100M upfront plus milestones up to $280M
--------------------------------------------------------------------------------

- Upfront: $20M cash plus ~$80M in Erasca common stock (private placement, 6-mo lock-up).
- Regulatory milestones up to $80M; sales milestones up to $200M; low-single-digit royalties.
- Exclusive worldwide license to develop, manufacture, and commercialize naporafenib.
- Novartis reserves right to use IP for non-clinical research and ongoing trials.
- Company presentation (Exhibit 99.1) provides naporafenib overview.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000119312522301402/0001193125-22-301402-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000119312522301402/d429778d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-301402

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer